Cancer Epidemiology
Volume 34, Issue 5 , Pages 639-643 , October 2010

The impact of menopausal hormone therapy on the incidence of different breast cancer types – Data from the Cancer Registry Hamburg 1991–2006

  • S. Hentschel

      Affiliations

    • Hamburg Cancer Registry, Ministry of Health and Social Affairs, Hamburg, Germany
    • Corresponding Author InformationCorresponding author at: Hamburgisches Krebsregister, Billstrasse 80, D 20539 Hamburg, Germany. Fax: +49 40 428 37 2655.
    • ,
  • J. Heinz

      Affiliations

    • Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • S. Schmid-Höpfner

      Affiliations

    • Hamburg Cancer Registry, Ministry of Health and Social Affairs, Hamburg, Germany
    • ,
  • N. Obi

      Affiliations

    • Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • E. Vettorazzi

      Affiliations

    • Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • J. Chang-Claude

      Affiliations

    • Department of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
    • ,
  • D. Flesch-Janys

      Affiliations

    • Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

,Accepted 8 July 2010.

References 

  1. Writing Group for the Women's Health Initiative . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomised controlled trial. JAMA. 2002;288(3):321–333
  2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28
  3. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99(15):1152–1161
  4. Stewart SL, Sabatino SA, Forster SL, Richardson LC. Decline in breast cancer incidence – United States 1999–2003. MMWR. 2007;56:549–553
  5. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335–1339
  6. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25(23):3437–3439
  7. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107(3):427–430
  8. Katalinic A, Stegmaier C, Rawal R, Waldmann A. Weniger Hormonersatztherapie, weniger Brustkrebs in Deutschland?. Geburtshilfe und Frauenheilkunde. 2007;(11):1217–1221
  9. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573–587
  10. Brewster DH, Sharpe KH, Clark DI, Collins J. Declining breast cancer incidence and decreased HRT use. Lancet. 2009;373(9662):459–460
  11. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer. 2009;45(9):1649–1653
  12. In: 6th ed.. Robert Koch-Institute , Association of Population-based Cancer Registries in Germany  editor. Cancer in Germany, 2003–2004. Incidence and Trends. 2008;
  13. Flesch-Janys D, Slanger T, Mutschelknaus E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933–941
  14. Ravdin PM, Cronin KA, Howlader N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treat. 2006;100(Suppl. 1):S6
  15. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670–1674
  16. Kliewer EV, Demers AA, Nugent ZJ. A decline in breast-cancer incidence. N Engl J Med. 2007;357(5):509–510
  17. Colditz GA. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 2007;9(4):108
  18. Zahl PH, Maehlen J. A decline in breast-cancer incidence. N Engl J Med. 2007;357(5):510–511
  19. Ponti A, Rosso S, Zanetti R, Ricceri F, Tomatis M, Segnan N. Re: breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99(23):1817–1818
  20. Soerjomataram I, Coebergh JW, Louwman MWJ, Visser O, van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol. 2007;25(31):5038–5039
  21. Robbins AS, Clarke CA. Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(23):1815–1817
  22. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008;188(11):641–644
  23. Bouchardy C, Fioretta G, Verkooijen HM, Vlastos G, Schaefer P, Delaloye J-F, et al. Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer. 2007;96(11):1743–1746
  24. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol. 2008;19(6):1187–1194
  25. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24(33):e49–e50
  26. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–741
  27. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95(12):2455–2464
  28. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88(11):2570–2577
  29. Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat. 2009;118:425–432
  30. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer incidence in five continents. IARC Scientific Publications No. 160, 2007; vol. IX. p. 307.
  31. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  32. Koch K. Hormonersatz-Therapie: Rechnung mit Unbekannten. Dtsch Ärzteblatt. 2000;97(33):A-2145–A-2146
  33. Koch K, Greiser E. Hormonersatz-Therapie: Rechnung mit Unbekannten. Dtsch Ärztbl. 2000;97(39):A-2512
  34. Biglia N, Mariani L, Robba C, Moggio G, Sismondi P. Hormone-replacement therapy and lobular cancers: new deals and old myths. Expert Rev Endocrinol Metab. 2008;3(3):287–290
  35. Weedon-Fekjaer H, Sørum R, Brenn MK. Hormone therapy use may explain recent results regarding tumor regression. Arch Intern Med. 2009;169(May (10)):996–997

PII: S1877-7821(10)00136-0

doi: 10.1016/j.canep.2010.07.010

Cancer Epidemiology
Volume 34, Issue 5 , Pages 639-643 , October 2010

Article Tools

* Image Usage & Resolution